Copertina

Antimeningococcal protection in patients receiving terminal complement inhibitors

Introduction - C5 inhibitor (C5i) therapy markedly increases susceptibility to invasive meningococcal disease (IMD) by blocking the terminal complement pathway essential for defense against Neisseria meningitidis. Vaccination is recommended for all recipients, yet breakthrough infections persist. An...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Vujović, Aleksandra (Autore) , Schaefer, Franz (Autore) , Sellier-Leclerc, Anne-Laure (Autore) , Parolin, Mattia (Autore) , Pérez-Beltrán, Víctor (Autore) , Hofstetter, Jonas (Autore) , Boyer, Olivia (Autore) , Mancuso, Maria Cristina (Autore) , Habbig, Sandra (Autore) , Levart, Tanja Kersnik (Autore)
Natura: Article (Journal)
Lingua:inglese
Pubblicazione: February 2026
In: Kidney international. Reports
Year: 2026, Volume: 11, Fascicolo: 2, Pages: 1-10
ISSN:2468-0249
DOI:10.1016/j.ekir.2025.11.025
Accesso online:Resolving-System, kostenfrei, Volltext: https://doi.org/10.1016/j.ekir.2025.11.025
Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S2468024925007107
Testo
Note sull'autore:Aleksandra Vujović, Franz Schaefer, Anne-Laure Sellier-Leclerc, Mattia Parolin, Víctor Pérez-Beltrán, Jonas Hofstetter, Olivia Boyer, Maria Cristina Mancuso, Sandra Habbig, and Tanja Kersnik Levart, on behalf of the ERKNet TMA Working Group and Other Collaborators
Descrizione
Riassunto:Introduction - C5 inhibitor (C5i) therapy markedly increases susceptibility to invasive meningococcal disease (IMD) by blocking the terminal complement pathway essential for defense against Neisseria meningitidis. Vaccination is recommended for all recipients, yet breakthrough infections persist. Antibiotic prophylaxis is not universally endorsed, resulting in variable practices. We aimed to assess whether antibiotic prophylaxis provides additional protection beyond vaccination in C5i-treated patients. - Methods - The analysis included 124 C5i recipients treated for > 6 months. Patients were classified as receiving single protection (vaccination or antibiotic prophylaxis alone) or combined protection (vaccination and continuous antibiotic prophylaxis). The outcomes were analyzed by prescribed and by implemented regimen; the latter accounting for patient adherence to antibiotic prophylaxis. - Results - Of the patients, 60% were prescribed combined protection. Booster vaccination coverage was low (< 40%), and one-quarter of patients did not adhere to antibiotic prophylaxis. The overall incidence of IMD was 0.74 cases per 100 patient-years (PY) (95% confidence interval [CI]: 0.37-1.32). After accounting for noncompliance, the incidence of IMD remained significantly lower in the combined protection group (3.1 [95% CI: 1.5-4.8] vs. 0.5 [95% CI: 0.0-2.7], P = 0.03), corresponding to a 6-fold reduction in risk. Eleven infections were reported, predominantly due to serogroup B (45.5%). Ten patients recovered completely, and 1 had mild residual disability. - Conclusion - Although guidelines recommend vaccination alone, our findings indicate that combined protection offers substantially greater protection against IMD in patients receiving long-term C5i. Continued prospective monitoring will be essential to define the optimal preventive strategies in this high-risk population.
Descrizione del documento:Online verfügbar: 25. November 2025, Artikelversion: 05. Januar 2026
Gesehen am 13.05.2026
Descrizione fisica:Online Resource
ISSN:2468-0249
DOI:10.1016/j.ekir.2025.11.025

Documenti analoghi